Sardona Therapeutics operates a preclinical biotechnology platform that develops small molecule drugs targeting RNA-binding proteins and spliceosome components to address therapy-resistant cancers. By linking these targets to clinically validated genetic alterations, the company aims to create precision medicine options for patients with metastatic cancers such as breast cancer and non-small cell lung cancer.
Funding
$100K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers develop resistance to existing therapies due to dysregulation of RNA processing and aberrant function of RNA-binding proteins (RBPs). Traditional drug discovery methods struggle to target these previously undruggable oncogenic drivers, leaving a significant unmet need for patients with metastatic cancers.
Solution
Sardona Therapeutics is developing a platform for precision medicine that targets RNA-binding proteins (RBPs) and spliceosome components to create small molecule drugs for therapy-resistant cancers. The platform utilizes a proprietary RBP Topography Map, linking specific RBPs to therapy-resistant cancers. Sardona leverages internally developed screening assays, bioinformatics capabilities, and focused small molecule compound libraries to generate drug candidates that inhibit previously undruggable oncogenic drivers. This approach aims to address high unmet needs in genetically defined, metastatic cancers, including breast cancer, non-small cell lung cancer, and colorectal cancer, and may have applications beyond oncology.
Target Audience
The primary target audience includes patients with genetically defined, metastatic cancers such as breast cancer, non-small cell lung cancer, and colorectal cancer, as well as the clinicians who treat them.
Features
- Proprietary RBP Topography Map linking RBPs to specific therapy-resistant cancers
- Screening assays for identifying small molecule drugs that target RBPs
- Bioinformatics capabilities for analyzing RBP-driven biology
- Focused small molecule compound libraries for generating drug candidates
- Compounds designed to inhibit previously undruggable oncogenic drivers
- Precision oncology approach targeting clinically established oncogenic pathways